Mar 5, 20211 min
$CYDY (%) Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab source
$KROS (%) presented preclinical results of KER-050 and ALK2 inhibitors at ESH source
$ONCY (%) Oncolytics entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity source